Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bell, Catherine C ^a   Hendriks, Delilah F G ^a   Moro, Sabrina M L ^a   Ellis, Ewa ^b   Walsh, Joanne ^c   Renblom, Anna ^a   Fredriksson Puigvert, Lisa ^a   Dankers, Anita C A ^d   Jacobs, Frank ^d   Snoeys, Jan ^d   Sison Young, Rowena L ^c   Jenkins, Rosalind E ^c   Nordling, Åsa ^a   Mkrtchian, Souren ^a   Park, B Kevin ^c   Kitteringham, Neil R ^c   Goldring, Christopher E P ^c   Lauschke, Volker M ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FIALURIDINE; PROTEOME; URACIL ARABINOSIDE;

ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECTS; HUMAN; LIVER CELL; MULTICELLULAR SPHEROID; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROOF OF CONCEPT; TOXIC HEPATITIS;

ARABINOFURANOSYLURACIL; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; PROOF OF CONCEPT STUDY; PROTEOME; SPHEROIDS, CELLULAR;

EID: 84965172494     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25187     Document Type: Article

References (45)

1. Gómez-Lechón, M. J., Tolosa, L., Conde, I. & Donato, M. T. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin. Drug Metab. Toxicol. 10, 1553-1568, doi: 10.1517/17425255.2014.967680 (2014).
2. Hewitt, N. J. et al. Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies. Drug Metab. Rev. 39, 159-234, doi: 10.1080/03602530601093489 (2015).
3. Rowe, C. et al. Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology 58, 799-809, doi: 10.1002/hep.26414 (2013).
4. Elaut, G. et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr. Drug Metab. 7, 629-660 (2006).
5. Lin, R.-Z., Chou, L.-F., Chien, C.-C. M. & Chang, H.-Y. Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and β 1-integrin. Cell Tissue Res. 324, 411-422, doi: 10.1007/s00441-005-0148-2 (2006).
6. Kern, A., Bader, A., Pichlmayr, R. & Sewing, K. F. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem. Pharmacol. 54, 761-772, doi: 10.1016/S0006-2952(97)00204-9 (1997).
7. Mueller, D. et al. In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J. Tissue Eng. Regen. Med. 5, e207-e218, doi: 10.1002/term.418 (2011).
8. Feng, Z.-Q. et al. The effect of nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte aggregates and the maintenance of liver function. Biomaterials 30, 2753-2763, doi: 10.1016/j.biomaterials.2009.01.053 (2009).
9. Schutte, M. et al. Rat Primary Hepatocytes Show Enhanced Performance and Sensitivity to Acetaminophen During Three-Dimensional Culture on a Polystyrene Scaffold Designed for Routine Use. Assay Drug Dev. Technol. 9, 475-486, doi: 10.1089/adt.2011.0371 (2011).
10. Vinci, B. et al. Modular bioreactor for primary human hepatocyte culture: Medium flow stimulates expression and activity of detoxification genes. Biotechnol. J. 6, 554-564, doi: 10.1002/biot.201000326 (2011).
11. Godoy, P. et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and nonparenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87, 1315-1530, doi: 10.1007/s00204-013-1078-5 (2013).
12. Khetani, S. R. et al. Microengineered Liver Tissues for Drug Testing. J. Lab. Autom. 20, 216-250, doi: 10.1177/2211068214566939 (2015).
13. Landry, J., Bernier, D., Ouellet, C., Goyette, R. & Marceau, N. Spheroidal aggregate culture of rat liver cells: histotypic reorganization, biomatrix deposition, and maintenance of functional activities. J. Cell Biol. 101, 914-923, doi: 10.1083/jcb.101.3.914 (1985).
14. Tostões, R. M. et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 55, 1227-1236, doi: 10.1002/hep.24760 (2012).
15. Messner, S., Agarkova, I., Moritz, W. & Kelm, J. M. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch. Toxicol. 87, 209-213, doi: 10.1007/s00204-012-0968-2 (2012).
16. Ohkura, T. et al. Evaluation of Human Hepatocytes Cultured by Three-dimensional Spheroid Systems for Drug Metabolism. Drug Metab. Pharmacokinet. 29, 373-378, doi: 10.2133/dmpk.DMPK-13-RG-105 (2014).
17. McKenzie, R. et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333, 1099-1105, doi: 10.1056/NEJM199510263331702 (1995).
18. Fukuhara, Y. et al. Gene expression profile in the regenerating rat liver after partial hepatectomy. J. Hepatol. 38, 784-792, doi: 10.1016/S0168-8278(03)00077-1 (2003).
19. Lin, R.-Z. & Chang, H.-Y. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol. J. 3, 1172-1184, doi: 10.1002/biot.200700228 (2008).
20. Jungermann, K. & Kietzmann, T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu. Rev. Nutr. 16, 179-203, doi: 10.1146/annurev.nu.16.070196.001143 (1996).
21. Pourbaix, S., Berger, Y., Desager, J. P., Pacco, M. & Harvengt, C. Absolute bioavailability of amiodarone in normal subjects. Clin. Pharmacol. Ther. 37, 118-123 (1985).
22. Gutierrez, M. M., Nicolas, L. B., Donazzolo, Y. & Dingemanse, J. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation. Int. J. Clin. Pharmacol. Ther. 51, 529-536, doi: 10.5414/CP201806 (2013).
23. G.D. Searle LLC Division of Pfizer Inc., FDA professional drug information - Arthrotec (2015) Available at: http://www.drugs.com/pro/arthrotec.html (Accessed: 3rd April 2016).
24. Bowsher, R. R. et al. Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 38, 2134-2142, doi: 10.1097/00007890-200607152-01711 (1994).
25. Jorga, K., Fotteler, B., Heizmann, P. & Gasser, R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br. J. Clin. Pharmacol. 48, 513-520, doi: 10.1046/j.1365-2125.1999.00036.x (2001).
26. Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45, doi: 10.1016/S0008-6363(02)00846-5 (2003).
27. Muller, P. Y. & Milton, M. N. The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751-761, doi: 10.1038/nrd3801 (2012).
28. Anthérieu, S. et al. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. Hepatology 57, 1518-1529, doi: 10.1002/hep.26160 (2013).
29. Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Eng. J. Med. 362, 1675-1685, doi: 10.1056/NEJMoa0907929 (2010).
30. Shaw, P. J., Hopfensperger, M. J., Ganey, P. E. & Roth, R. A. Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-Alpha. Toxicol. Sci. 100, 259-266, doi: 10.1093/toxsci/kfm218 (2007).
31. Rodríguez-Antona, C. et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32, 505-520, doi: 10.1080/00498250210128675 (2002).
32. Sison-Young, R. L. C. et al. Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. Toxicol. Sci. 147, 412-424, doi: 10.1093/toxsci/kfv136 (2015).
33. LeCluyse, E. L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13, 343-368, doi: 10.1016/S0928-0987(01)00135-X (2001).
34. Wu, G., Fang, Y.-Z., Yang, S., Lupton, J. R. & Turner, N. D. Glutathione metabolism and its implications for health. J. Nutr. 134, 489-492, doi: 10.1016/B978-0-408-71015-2.50010-9 (2004).
35. Kaplowitz, N. Drug-induced liver injury. Clin. Effect. Dis. 38 Suppl 2, S44-48, doi: 10.1086/381446 (2004).
36. Xu, D. et al. Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing. PLoS Med. 11, e1001628, doi: 10.1371/journal.pmed.1001628 (2014).
37. Sim, S. C. & Ingelman-Sundberg, M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol. Sci. 32, 72-81, doi: 10.1016/j.tips.2010.11.008 (2011).
38. Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and Individualized Drug Therapy. Annu. Rev. Med. 57, 119-137, doi: 10.1146/annurev.med.56.082103.104724 (2006).
39. Takayama, K. et al. Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc. Natl. Acad. Sci. USA 111, 16772-16777, doi: 10.1073/pnas.1413481111 (2014).
40. Zhang, S. Y., Surapureddi, S., Coulter, S., Ferguson, S. S. & Goldstein, J. A. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol. Pharmacol. 82, 529-540, doi: 10.1124/mol.112.078386 (2012).
41. Liguori, M. J. et al. Comparison of TNFα to Lipopolysaccharide as an Inflammagen to Characterize the Idiosyncratic Hepatotoxicity Potential of Drugs: Trovafloxacin as an Example. Int. J. Mol. Sci. 11, 4697-4714, doi: 10.3390/ijms11114697 (2010).
42. Strom, S. C. et al. Use of human hepatocytes to study P450 gene induction. Methods Enzymol. 272, 388-401 (1996).
43. Walsh, J. et al. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: Biochemical, pharmacological and toxicological implications. J. Proteomics 108, 171-187, doi: 10.1016/j.jprot.2014.05.007 (2014).
44. Stabenow, D. et al. Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology 51, 1430-1437, doi: 10.1002/hep.23575 (2010).
45. Fuhrmann, A. et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem. Pharmacol. 88, 216-228, doi: 10.1016/j.bcp.2014.01.020 (2014).